ReviewTherapeutic advances in gastroenterology2024
Microbiota restoration therapies for recurrent
Review in Therapeutic advances in gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Synthetic microbial communities: emerging live biotherapeutics for targeted gut microbiome modulation.Gut microbes · 2026Review
- Microbiome-based therapeutics forGut microbes · 2026Review
- The gut microbiota as a regulator of intestinal stem-cell fate: bacterial and fungal control of differentiation and regeneration.Gut microbes · 2026Review
- Clinical Outcomes of Metronidazole Monotherapy Versus Metronidazole PlusBiotech (Basel (Switzerland)) · 2026Article
- Association between Clostridioides difficile Test Positivity and Colorectal Cancer Incidence in a Multisite Hospital-Based Retrospective Cohort Analysis.Cancer research communications · 2026Observational
- Dynamics of the microbiota in patients with Clostridioides difficile: Recurrence, treatment, sex, and immunosuppression.PLoS pathogens · 2026Article
- [New antimicrobial substances to combat increasing resistance].Innere Medizin (Heidelberg, Germany) · 2026Review
- Microbiota-Driven Strategies for Managing IBD-Associated Risks: From Infections to Mental Health.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Gut microbiota dysbiosis: Pathogenic drivers and emerging phage-based therapeutics.AIMS microbiology · 2026Review
- Inhibition ofACS omega · 2025Article
- The ladder of regulatory stringency and balance: an application to the US FDA's regulation of bacterial live therapeutics.Gut microbes · 2025Review
- Microbiome Therapeutics for Clostridioides difficile Infection.Infectious disease clinics of North America · 2025Review
- Inhibition ofbioRxiv : the preprint server for biology · 2025Article
- The global resistance problem and the clinical antibacterial pipeline.Nature reviews. Microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbiota restoration therapy has become a standard treatment for recurrent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.